Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
Semaglutide is a medication commonly prescribed to manage Type 2 Diabetes (T2D) and obesity. It is marketed under brand names such as Ozempic and Wegovy. This drug helps patients control their blood sugar levels and lose weight. However, recent studies have raised concerns about a potential link between semaglutide and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), a serious condition that can cause sudden vision loss due to damage to the optic nerve.
Parker Waichman LLP is a national product injury law firm dedicated to representing victims of defective drugs and products. Our firm is currently investigating claims related to semaglutide and its association with NAION. Our goal is to help those affected by this dangerous side effect seek justice and recover monetary compensation for their injuries. We understand the profound impact that such injuries can have on individuals and their families, and we are unwavering in our commitment to holding pharmaceutical companies accountable for the safety of their products. If you or a loved one have been harmed affected are encouraged to contact us today at 1-800-YOUR-LAWYER (1-800-968-7529) to understand their legal rights and options.
Understanding the Study’s Findings
The primary finding of this study is that patients prescribed semaglutide have an increased risk of developing NAION. Despite extensive research, the exact cause of NAION remains unclear. The incidence rate of NAION is 2 to 10 cases per 100,000 people, making it the second most common cause of blindness due to optic nerve damage after glaucoma. The Cox regression analyses indicated high hazard ratios (4.28 and 7.64 for T2D and overweight or obese cohorts, respectively), highlighting a substantially increased risk of NAION in individuals taking semaglutide compared to those on other medications for T2D and obesity. This elevated risk does not appear to be related to differences in baseline characteristics between the cohorts.
The study’s strengths include a relatively large sample size of 629 NAION cases over six years, which represents a significant portion of the expected cases in the Boston area. Diagnoses of NAION were confirmed by experienced neuro-ophthalmologists, and all records coded as ischemic optic neuropathy were manually reviewed to ensure accurate diagnosis. Additionally, the study employed propensity score matching to balance cohorts and reduce selection bias. Cox regression was also used to estimate the association between semaglutide and the risk of NAION more precisely.
Increasing Use and Risks of GLP-1 RA Drugs
The first two injectable GLP-1 receptor agonists (Ozempic and Wegovy) have become widely prescribed, with semaglutide making up 1.7% of all prescriptions in the United States by April 2023. New formulations of these drugs are FDA-approved, and their use is expected to expand due to their medical benefits and popularity. This trend may lead to a rise in NAION cases linked to these medications.
Reported Injuries: NAION
Explanation of NAION and Its Symptoms
Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) is a serious eye condition that results in sudden vision loss. NAION occurs when there is insufficient blood flow to the optic nerve, leading to damage and potential permanent vision loss. This condition typically affects one eye at a time, but it can occur in both eyes sequentially. The symptoms of NAION include sudden, painless vision loss, often noted upon waking, as well as a decrease in the sharpness of vision and loss of peripheral vision. Patients may also experience visual field defects, such as missing areas in their vision and difficulty with color vision.
Study Findings Linking Semaglutide to an Increased Risk of NAION
Recent studies have drawn a significant connection between the use of semaglutide and an increased risk of developing NAION. Semaglutide is a GLP-1 receptor agonist used to manage Type 2 Diabetes (T2D) and obesity. While effective in controlling blood sugar levels and promoting weight loss, this medication has been linked to serious adverse effects, including NAION.
In a study involving 442 patients without a history of NAION, researchers conducted secondary analyses for baseline variables that differed by 20% or more between two cohorts. These variables included systemic hypertension, T2D, hyperlipidemia, and obstructive sleep apnea. Using 1:1 propensity and exact matches, they found a higher risk of NAION in patients using semaglutide compared to those not using the drug. The Cox proportional hazards regression model revealed a hazard ratio (HR) of 7.28 (95% CI, 1.59-33.34; p = .01), indicating a significantly higher risk of NAION in the semaglutide cohort.
The Semaglutide NAION Lawsuit Process
The first step in the lawsuit process is to schedule an initial consultation with Parker Waichman LLP. During this free case evaluation, our legal team will review the details of your situation to determine if you have a viable claim. We will discuss your medical history, the use of semaglutide, and the onset of NAION symptoms. This consultation is crucial in understanding your legal rights and options for pursuing compensation.
Free Case Evaluation Process
Our free case evaluation process is designed to provide you with a comprehensive understanding of your potential case. We will assess the evidence you provide, including medical records, prescriptions, and any other relevant documentation. Our attorneys will explain the legal process in plain language, potential outcomes, and the steps involved in pursuing a lawsuit. This evaluation is offered at no cost to you and without any obligation.
Investigation
Once you decide to proceed with a lawsuit, our team will begin a thorough investigation. This involves gathering all necessary evidence to build a strong case. We will collect your medical records, prescriptions, and any expert testimonies that can support your claim. Our goal is to establish a clear link between the use of semaglutide and the development of NAION. We will keep you informed at every step of the investigation, ensuring you are always aware of the progress of your case.
Gathering Evidence
The evidence-gathering process is critical in substantiating your claim. We will work with top-tier medical experts to review your records and provide testimonies on the connection between semaglutide and NAION. This includes examining your medical history, treatment plans, and the timing of your symptoms relative to the use of semaglutide. Our team will also gather any additional documentation that can support your case.
Filing the Lawsuit
After the investigation, we will prepare and file the lawsuit on your behalf. This involves drafting legal documents that outline your claims and submitting them to the appropriate court. We will ensure that all paperwork is accurately completed and filed within the statute of limitations.
Preparing and Submitting Legal Documents
Our attorneys will meticulously prepare all legal documents necessary for your case. This includes the complaint, which details the facts of your case and the legal basis for your claims. We will also prepare any supporting documents required by the court. Once everything is in order, we will submit these documents to initiate the legal proceedings.
Discovery Phase
The discovery phase is a crucial part of the lawsuit process, where both sides exchange information and evidence. This phase includes depositions, interrogatories, and document requests. Our attorneys will work diligently to gather all relevant information from the defendants and provide them with the necessary documents from our side.
Exchange of Information and Evidence
During discovery, we will request documents, records, and other evidence from the defendants. This includes internal company documents, communications, and any other materials that can support your claim. We will also provide the defendants with the requested information from our side, ensuring a transparent exchange of evidence.
Depositions, Interrogatories, and Document Requests
Depositions involve taking sworn statements from witnesses and experts, which are recorded for use in court. Interrogatories are written questions that the opposing party must answer under oath. Document requests involve obtaining specific records and documents from the defendants. These tools help build a strong case by uncovering vital information.
Settlement Negotiations
Throughout the lawsuit process, we will engage in settlement negotiations with the defendants. Our goal is to secure a fair settlement that compensates you for your injuries and damages. We will use the evidence gathered during discovery to negotiate from a position of strength.
Negotiating with Defendants for a Fair Settlement
Our attorneys will negotiate vigorously with the defendants to achieve a settlement that reflects the extent of your injuries and losses. We will present the evidence, including expert testimonies and medical records, to demonstrate the impact of semaglutide on your health. If a satisfactory settlement is not reached, we are prepared to take your case to trial.
Trial
If settlement negotiations do not result in a fair agreement, we will proceed to trial. Our experienced trial lawyers will present your case in court, fighting for the maximum compensation you deserve. We will use all the evidence and testimonies gathered during the investigation and discovery phases to make a compelling case before the judge and jury.
Why Choose Parker Waichman LLP?
Parker Waichman LLP has decades of experience handling product liability cases. Our attorneys have a deep understanding of the legal complexities involved in these cases and have successfully represented numerous clients in similar situations. We are dedicated to holding pharmaceutical companies accountable for the safety of their products.
Proven Track Record
Our firm has recovered over $2 billion in settlements and verdicts for our clients. This impressive track record demonstrates our commitment to achieving justice and fair compensation for those harmed by defective products. We have the skills and resources necessary to handle complex litigation and secure favorable outcomes.
No Fees Unless We Win
At Parker Waichman LLP, we work on a contingency fee basis. This means you pay nothing out of pocket for our services. We only collect a fee if we recover compensation for you. This arrangement ensures that you can pursue your case without financial risk, allowing you to focus on your recovery while we handle the legal aspects.
Respected by Our Peers
Our firm has earned top ratings from AVVO, Martindale-Hubbell, and Lawdragon, reflecting our reputation for excellence in the legal community. We are highly respected by our peers, judges, and former clients, who recognize our dedication and skill in handling personal injury and product liability cases.
We provide personalized attention and support throughout the entire legal process. From the initial consultation to the final resolution of your case, our attorneys will be with you every step of the way. We understand the challenges you face and are committed to providing compassionate and effective representation.
.svg){kind=small}
.avif)
.avif)
